On Monday, October 19 Disc Medicine announced that its APOLLO Phase 3 clinical trial of bitopertin topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints.

In this Community Call, UPA was joined by Disc Medicine leadership and porphyria expert Amy Yeung, MD to discuss:

• The results of the APOLLO Phase 3 clinical trial and their significance

• Timeline and next steps for bitopertin

• Disc Medicine’s message to the porphyria community

Interested in bitopertin? Patients in the United States may be able to access bitopertin through the Disc Expanded Access Program (EAP). Learn more about the program here.

Bitopertin is an investigational treatment and has not been approved by the FDA. This message is for information only and is not medical advice.